Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Starling OncologySTLN +5.56%56 FCF Margin % is -2.21% as of Mar. 2026. GuruFocus rates STLN with a GF Score™ of 56/100 and a GF Value™ of $2.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Starling Oncology ranks worse than 69.37% on this metric.
The historical data trend for Starling Oncology's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Starling Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starling Oncology FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Starling Oncology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Starling Oncology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starling Oncology (STLN) has a FCF Margin % of -2.21% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Starling Oncology and its competitors. According to the industry distribution chart, Starling Oncology ranks #462 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 69.4%.
Is Starling Oncology's FCF Margin % too high?
Starling Oncology's current FCF Margin % is -2.21%. Based on the distribution chart, Starling Oncology ranks #462 out of 666 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Starling Oncology has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's FCF Margin % compare to SRTA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Starling Oncology ranks #462 out of 666 companies for FCF Margin %. This places Starling Oncology in the lower half of its industry. The industry median FCF Margin % is 3.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.23, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Starling Oncology and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starling Oncology's current FCF Margin % is -2.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.29, compared to a current price of $5.17 — trading 125.8% above its estimated fair value. The current FCF Margin % is -2.21%. Starling Oncology's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Starling Oncology (STLN), the current FCF Margin % is -2.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starling Oncology (STLN) Overvalued in 2026?
Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued.
The current stock price of $5.17 is trading 125.8% above its estimated GF Value™ of $2.29.
GuruFocus considers Starling Oncology to be Significantly Overvalued.
Key valuation signals for STLN:
FCF Margin %: -2.21%
GF Value™: $2.29 vs. price of $5.17 (125.8% above fair value)
No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for STLN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STLN has been successfully added to your 
